Bryan T J Hennessy

Summary

Publications

  1. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  2. ncbi Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
  3. ncbi Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
  4. ncbi c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
    Pablo Vivas-Mejia
    Department of Experimental Therapeutics, Center for RNAi and non coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:184-94. 2010

Collaborators

  • L Rubin
  • Mark S Carey
  • Yang Li
  • Jie Li
  • Karen H Lu
  • Ariel Fernandez
  • Maurie Markman
  • Ana M Gonzalez-Angulo
  • Ana Lluch
  • Gordon B Mills
  • Chad J Creighton
  • Pablo Vivas-Mejia
  • Lajos Pusztai
  • Lei Deng
  • Sam Aparicio
  • Wenbin Liu
  • Russell Broaddus
  • Jan Alsner
  • Gabriel N Hortobagyi
  • Powel Brown
  • Funda Meric-Bernstam
  • Aysegul Sahin
  • Jens Overgaard
  • Anne Lise Borresen-Dale
  • W Fraser Symmans
  • Kevin R Coombes
  • Corey Speers
  • Simen Myhre
  • Zhenlin Ju
  • Yvonne G Lin
  • Lingegowda Mangala
  • Zhengong Peng
  • Hee Dong Han
  • Adrian V Lee
  • Angela Sanguino
  • William Bornmann
  • Susan G Hilsenbeck
  • Hye Sun Kim
  • Joe W Gray
  • Ana Maria Gonzalez-Angulo
  • Yiqun Zhang
  • Angelo J Casa
  • Juliana Maria Benito
  • Francois Xavier Claret
  • Gabriel Lopez-Berestein
  • Xiaoyong Fu
  • C Kent Osborne
  • Rachel Schiff
  • Cristian Rodriguez-Aguayo
  • Powell H Brown
  • Anil K Sood
  • Arturo Chavez-Reyes
  • Rebecca L Stone
  • Alpa M Nick

Detail Information

Publications4

  1. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  2. ncbi Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  3. ncbi Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
    ..3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs...
  4. ncbi c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
    Pablo Vivas-Mejia
    Department of Experimental Therapeutics, Center for RNAi and non coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:184-94. 2010
    ..To show the functional, clinical, and biological significance of c-Jun-NH(2)-kinase (JNK)-1 in ovarian carcinoma...